Intelligent Bio Solutions Inc. provided unaudited preliminary earnings guidance for the second quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | -2.09% | -6.40% | -42.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.29% | 6.8M | |
-27.90% | 9.96B | |
-4.81% | 3.03B | |
+31.37% | 3B | |
-14.73% | 2.18B | |
-14.39% | 1.76B | |
+70.99% | 1.42B | |
+23.17% | 794M | |
-2.18% | 756M | |
+3.18% | 305M |
- Stock Market
- Equities
- INBS Stock
- News Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023